Literature DB >> 2452434

Benign prostatic hyperplasia. Universal problem among aging men.

R A Smith1, R Wake, M S Soloway.   

Abstract

Benign prostatic hyperplasia (BPH) is a nonmalignant, age-related condition that affects most men who enjoy a long life. The diagnosis of BPH is generally straightforward and easily established. At the present time, transurethral resection of the prostate is considered the best mode of therapy for symptomatic BPH requiring active intervention. However, since people are likely to avoid surgery when provided a reasonable alternative, it is likely that pharmacologic treatments will be tried with increasing frequency.

Entities:  

Mesh:

Year:  1988        PMID: 2452434     DOI: 10.1080/00325481.1988.11700255

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  2 in total

1.  LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.

Authors:  K S Hirsch; C D Jones; J E Audia; S Andersson; L McQuaid; N B Stamm; B L Neubauer; P Pennington; R E Toomey; D W Russell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

2.  Symptomatic comparison in efficacy on patients with benign prostatic hyperplasia treated with two therapeutic approaches.

Authors:  Shao Li; Aiping Lu; Yongyan Wang
Journal:  Complement Ther Med       Date:  2009-12-02       Impact factor: 2.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.